ID   MAPK3_HUMAN             Reviewed;         382 AA.
AC   Q16644; B5BU67;
DT   06-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   12-OCT-2022, entry version 188.
DE   RecName: Full=MAP kinase-activated protein kinase 3;
DE            Short=MAPK-activated protein kinase 3;
DE            Short=MAPKAP kinase 3;
DE            Short=MAPKAP-K3;
DE            Short=MAPKAPK-3;
DE            Short=MK-3;
DE            EC=2.7.11.1;
DE   AltName: Full=Chromosome 3p kinase;
DE            Short=3pK;
GN   Name=MAPKAPK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND
RP   PHOSPHORYLATION.
RX   PubMed=8626550; DOI=10.1074/jbc.271.14.8488;
RA   McLaughlin M.M., Kumar S., McDonnell P.C., Van Horn S., Lee J.C.,
RA   Livi G.P., Young P.R.;
RT   "Identification of mitogen-activated protein (MAP) kinase-activated protein
RT   kinase-3, a novel substrate of CSBP p38 MAP kinase.";
RL   J. Biol. Chem. 271:8488-8492(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND PHOSPHORYLATION BY
RP   MAPK1/ERK2 AND MAPK3/ERK1.
RC   TISSUE=Heart;
RX   PubMed=8622688; DOI=10.1128/mcb.16.3.868;
RA   Sithanandam G., Latif F., Duh F.-M., Bernal R., Smola U., Li H., Kuzmin I.,
RA   Wixler V., Geil L., Shrestha S., Lloyd P.A., Bader S., Sekido Y.,
RA   Tartof K.D., Kashuba V.I., Zabarovsky E.R., Dean M., Klein G., Lerman M.I.,
RA   Minna J.D., Rapp U.R., Allikmets R.;
RT   "3pK, a new mitogen-activated protein kinase-activated protein kinase
RT   located in the small cell lung cancer tumor suppressor gene region.";
RL   Mol. Cell. Biol. 16:868-876(1996).
RN   [3]
RP   ERRATUM OF PUBMED:8622688.
RA   Sithanandam G., Latif F., Duh F.-M., Bernal R., Smola U., Li H., Kuzmin I.,
RA   Wixler V., Geil L., Shrestha S., Lloyd P.A., Bader S., Sekido Y.,
RA   Tartof K.D., Kashuba V.I., Zabarovsky E.R., Dean M., Klein G., Lerman M.I.,
RA   Minna J.D., Rapp U.R., Allikmets R.;
RL   Mol. Cell. Biol. 16:1880-1880(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CATALYTIC ACTIVITY, AND FUNCTION IN PHOSPHORYLATION OF HSPB1.
RX   PubMed=8774846; DOI=10.1016/0014-5793(96)00816-2;
RA   Clifton A.D., Young P.R., Cohen P.;
RT   "A comparison of the substrate specificity of MAPKAP kinase-2 and MAPKAP
RT   kinase-3 and their activation by cytokines and cellular stress.";
RL   FEBS Lett. 392:209-214(1996).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF HSPB1.
RX   PubMed=10383393; DOI=10.1074/jbc.274.27.18947;
RA   Rogalla T., Ehrnsperger M., Preville X., Kotlyarov A., Lutsch G.,
RA   Ducasse C., Paul C., Wieske M., Arrigo A.P., Buchner J., Gaestel M.;
RT   "Regulation of Hsp27 oligomerization, chaperone function, and protective
RT   activity against oxidative stress/tumor necrosis factor alpha by
RT   phosphorylation.";
RL   J. Biol. Chem. 274:18947-18956(1999).
RN   [9]
RP   INTERACTION WITH TCF3.
RX   PubMed=10781029; DOI=10.1074/jbc.c901040199;
RA   Neufeld B., Grosse-Wilde A., Hoffmeyer A., Jordan B.W., Chen P., Dinev D.,
RA   Ludwig S., Rapp U.R.;
RT   "Serine/Threonine kinases 3pK and MAPK-activated protein kinase 2 interact
RT   with the basic helix-loop-helix transcription factor E47 and repress its
RT   transcriptional activity.";
RL   J. Biol. Chem. 275:20239-20242(2000).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15302577; DOI=10.1016/j.yexcr.2004.05.027;
RA   Zakowski V., Keramas G., Kilian K., Rapp U.R., Ludwig S.;
RT   "Mitogen-activated 3p kinase is active in the nucleus.";
RL   Exp. Cell Res. 299:101-109(2004).
RN   [11]
RP   FUNCTION, MUTAGENESIS OF LYS-73, AND INTERACTION WITH PHC2 AND BMI1.
RX   PubMed=15563468; DOI=10.1074/jbc.m407155200;
RA   Voncken J.W., Niessen H., Neufeld B., Rennefahrt U., Dahlmans V.,
RA   Kubben N., Holzer B., Ludwig S., Rapp U.R.;
RT   "MAPKAP kinase 3pK phosphorylates and regulates chromatin association of
RT   the polycomb group protein Bmi1.";
RL   J. Biol. Chem. 280:5178-5187(2005).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF TAB3.
RX   PubMed=18021073; DOI=10.1042/bj20071149;
RA   Mendoza H., Campbell D.G., Burness K., Hastie J., Ronkina N., Shim J.H.,
RA   Arthur J.S., Davis R.J., Gaestel M., Johnson G.L., Ghosh S., Cohen P.;
RT   "Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the
RT   TAB3 regulatory subunit and activity of the TAK1 complex.";
RL   Biochem. J. 409:711-722(2008).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   FUNCTION.
RX   PubMed=20599781; DOI=10.1016/j.bcp.2010.06.021;
RA   Ronkina N., Menon M.B., Schwermann J., Tiedje C., Hitti E., Kotlyarov A.,
RA   Gaestel M.;
RT   "MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF
RT   biosynthesis via expression and phosphorylation of tristetraprolin.";
RL   Biochem. Pharmacol. 80:1915-1920(2010).
RN   [15]
RP   REVIEW.
RX   PubMed=18508601; DOI=10.2741/3095;
RA   Ronkina N., Kotlyarov A., Gaestel M.;
RT   "MK2 and MK3--a pair of isoenzymes?";
RL   Front. Biosci. 13:5511-5521(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [18]
RP   TISSUE SPECIFICITY, SUBCELLULAR LOCATION, INVOLVEMENT IN MDPT3, VARIANT
RP   MDPT3 PRO-173, AND CHARACTERIZATION OF VARIANT MDPT3 PRO-173.
RX   PubMed=26744326; DOI=10.1093/hmg/ddv624;
RA   Meunier I., Lenaers G., Bocquet B., Baudoin C., Piro-Megy C., Cubizolle A.,
RA   Quiles M., Jean-Charles A., Cohen S.Y., Merle H., Gaudric A., Labesse G.,
RA   Manes G., Pequignot M., Cazevieille C., Dhaenens C.M., Fichard A.,
RA   Ronkina N., Arthur S.J., Gaestel M., Hamel C.P.;
RT   "A dominant mutation in MAPKAPK3, an actor of p38 signaling pathway, causes
RT   a new retinal dystrophy involving Bruch's membrane and retinal pigment
RT   epithelium.";
RL   Hum. Mol. Genet. 25:916-926(2016).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 33-349 IN COMPLEX WITH INHIBITOR
RP   P4O.
RX   PubMed=19937655; DOI=10.1002/pro.294;
RA   Cheng R., Felicetti B., Palan S., Toogood-Johnson I., Scheich C.,
RA   Barker J., Whittaker M., Hesterkamp T.;
RT   "High-resolution crystal structure of human Mapkap kinase 3 in complex with
RT   a high affinity ligand.";
RL   Protein Sci. 19:168-173(2010).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.09 ANGSTROMS) OF 33-349 IN COMPLEX WITH INHIBITOR
RP   5B.
RX   PubMed=21565500; DOI=10.1016/j.bmcl.2011.04.018;
RA   Barf T., Kaptein A., de Wilde S., van der Heijden R., van Someren R.,
RA   Demont D., Schultz-Fademrecht C., Versteegh J., van Zeeland M., Seegers N.,
RA   Kazemier B., van de Kar B., van Hoek M., de Roos J., Klop H., Smeets R.,
RA   Hofstra C., Hornberg J., Oubrie A.;
RT   "Structure-based lead identification of ATP-competitive MK2 inhibitors.";
RL   Bioorg. Med. Chem. Lett. 21:3818-3822(2011).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-28; ALA-105 AND TYR-276.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Stress-activated serine/threonine-protein kinase involved in
CC       cytokines production, endocytosis, cell migration, chromatin remodeling
CC       and transcriptional regulation. Following stress, it is phosphorylated
CC       and activated by MAP kinase p38-alpha/MAPK14, leading to
CC       phosphorylation of substrates. Phosphorylates serine in the peptide
CC       sequence, Hyd-X-R-X(2)-S, where Hyd is a large hydrophobic residue.
CC       MAPKAPK2 and MAPKAPK3, share the same function and substrate
CC       specificity, but MAPKAPK3 kinase activity and level in protein
CC       expression are lower compared to MAPKAPK2. Phosphorylates HSP27/HSPB1,
CC       KRT18, KRT20, RCSD1, RPS6KA3, TAB3 and TTP/ZFP36. Mediates
CC       phosphorylation of HSP27/HSPB1 in response to stress, leading to
CC       dissociate HSP27/HSPB1 from large small heat-shock protein (sHsps)
CC       oligomers and impair their chaperone activities and ability to protect
CC       against oxidative stress effectively. Involved in inflammatory response
CC       by regulating tumor necrosis factor (TNF) and IL6 production post-
CC       transcriptionally: acts by phosphorylating AU-rich elements (AREs)-
CC       binding proteins, such as TTP/ZFP36, leading to regulate the stability
CC       and translation of TNF and IL6 mRNAs. Phosphorylation of TTP/ZFP36, a
CC       major post-transcriptional regulator of TNF, promotes its binding to
CC       14-3-3 proteins and reduces its ARE mRNA affinity leading to inhibition
CC       of dependent degradation of ARE-containing transcript. Involved in
CC       toll-like receptor signaling pathway (TLR) in dendritic cells: required
CC       for acute TLR-induced macropinocytosis by phosphorylating and
CC       activating RPS6KA3. Also acts as a modulator of Polycomb-mediated
CC       repression. {ECO:0000269|PubMed:10383393, ECO:0000269|PubMed:15563468,
CC       ECO:0000269|PubMed:18021073, ECO:0000269|PubMed:20599781,
CC       ECO:0000269|PubMed:8626550, ECO:0000269|PubMed:8774846}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:8774846};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:8774846};
CC   -!- ACTIVITY REGULATION: Activated following phosphorylation by p38-
CC       alpha/MAPK14 following various stresses. Inhibited by ligand 5B (2'-[2-
CC       (1,3-benzodioxol-5-yl)pyrimidin-4-yl]-5',6'-
CC       dihydrospiro[piperidine-4,7'-pyrrolo[3,2-c]pyridin]- 4'(1'h)-one) and
CC       ligand P4O (2-[2-(2-fluorophenyl)pyridin-4-yl]-1,5,6,7-tetrahydro- 4h-
CC       pyrrolo[3,2-c]pyridin-4-one), 2 ATP-competitive inhibitors.
CC   -!- SUBUNIT: Heterodimer with p38-alpha/MAPK14. The heterodimer with p38-
CC       alpha/MAPK14 forms a stable complex: molecules are positioned 'face to
CC       face' so that the ATP-binding sites of both kinases are at the
CC       heterodimer interface (By similarity). Interacts with TCF3 and with
CC       polycomb proteins, such as PCH2 and BMI1/PCGF4. {ECO:0000250,
CC       ECO:0000269|PubMed:10781029, ECO:0000269|PubMed:15563468,
CC       ECO:0000269|PubMed:19937655, ECO:0000269|PubMed:21565500}.
CC   -!- INTERACTION:
CC       Q16644; P04792: HSPB1; NbExp=3; IntAct=EBI-1384657, EBI-352682;
CC       Q16644; Q15759: MAPK11; NbExp=4; IntAct=EBI-1384657, EBI-298304;
CC       Q16644; Q16539: MAPK14; NbExp=10; IntAct=EBI-1384657, EBI-73946;
CC       Q16644; PRO_0000037566 [P27958]; Xeno; NbExp=5; IntAct=EBI-1384657, EBI-6377335;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15302577,
CC       ECO:0000269|PubMed:26744326}. Cytoplasm {ECO:0000269|PubMed:15302577,
CC       ECO:0000269|PubMed:26744326}. Note=Predominantly located in the
CC       nucleus, when activated it translocates to the cytoplasm.
CC   -!- TISSUE SPECIFICITY: Widely expressed, with a higher expression level
CC       observed in heart and skeletal muscle. No expression in brain.
CC       Expressed in the retinal pigment epithelium (PubMed:26744326).
CC       {ECO:0000269|PubMed:26744326, ECO:0000269|PubMed:8622688,
CC       ECO:0000269|PubMed:8626550}.
CC   -!- PTM: Phosphorylated and activated by MAPK1/ERK2 and MAPK3/ERK1.
CC       Phosphorylated and activated by MAP kinase p38-alpha/MAPK14 at Thr-201,
CC       Ser-251 and Thr-313 (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Macular dystrophy, patterned, 3 (MDPT3) [MIM:617111]: A form
CC       of retinal patterned dystrophy, characterized by retinal pigment
CC       epithelium and Bruch's membrane changes resembling a 'dry desert land'.
CC       It begins around the age of 30 and progresses to retinitis pigmentosa.
CC       MDPT3 inheritance is autosomal dominant. {ECO:0000269|PubMed:26744326}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U43784; AAC50428.1; -; mRNA.
DR   EMBL; U09578; AAD09136.1; -; mRNA.
DR   EMBL; AB451303; BAG70117.1; -; mRNA.
DR   EMBL; CH471055; EAW65131.1; -; Genomic_DNA.
DR   EMBL; BC001662; AAH01662.1; -; mRNA.
DR   EMBL; BC007591; AAH07591.1; -; mRNA.
DR   EMBL; BC010407; AAH10407.1; -; mRNA.
DR   CCDS; CCDS2832.1; -.
DR   PIR; JC6094; JC6094.
DR   RefSeq; NP_001230854.1; NM_001243925.1.
DR   RefSeq; NP_001230855.1; NM_001243926.1.
DR   RefSeq; NP_004626.1; NM_004635.4.
DR   PDB; 3FHR; X-ray; 1.90 A; A=33-349.
DR   PDB; 3FXW; X-ray; 2.00 A; A=33-349.
DR   PDB; 3R1N; X-ray; 2.09 A; A=33-349.
DR   PDB; 3SHE; X-ray; 2.25 A; A=33-349.
DR   PDB; 7NRB; X-ray; 1.90 A; A=33-349.
DR   PDBsum; 3FHR; -.
DR   PDBsum; 3FXW; -.
DR   PDBsum; 3R1N; -.
DR   PDBsum; 3SHE; -.
DR   PDBsum; 7NRB; -.
DR   AlphaFoldDB; Q16644; -.
DR   SMR; Q16644; -.
DR   BioGRID; 113617; 33.
DR   ELM; Q16644; -.
DR   IntAct; Q16644; 31.
DR   MINT; Q16644; -.
DR   STRING; 9606.ENSP00000396467; -.
DR   BindingDB; Q16644; -.
DR   ChEMBL; CHEMBL4670; -.
DR   DrugBank; DB08358; 2-(2-QUINOLIN-3-YLPYRIDIN-4-YL)-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE.
DR   DrugBank; DB07728; 2-[2-(2-FLUOROPHENYL)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE.
DR   GuidetoPHARMACOLOGY; 2095; -.
DR   iPTMnet; Q16644; -.
DR   PhosphoSitePlus; Q16644; -.
DR   BioMuta; MAPKAPK3; -.
DR   DMDM; 74762148; -.
DR   EPD; Q16644; -.
DR   jPOST; Q16644; -.
DR   MassIVE; Q16644; -.
DR   MaxQB; Q16644; -.
DR   PaxDb; Q16644; -.
DR   PeptideAtlas; Q16644; -.
DR   PRIDE; Q16644; -.
DR   ProteomicsDB; 60998; -.
DR   Antibodypedia; 30996; 339 antibodies from 32 providers.
DR   DNASU; 7867; -.
DR   Ensembl; ENST00000357955.6; ENSP00000350639.2; ENSG00000114738.11.
DR   Ensembl; ENST00000446044.5; ENSP00000396467.1; ENSG00000114738.11.
DR   Ensembl; ENST00000621469.5; ENSP00000478922.1; ENSG00000114738.11.
DR   GeneID; 7867; -.
DR   KEGG; hsa:7867; -.
DR   MANE-Select; ENST00000621469.5; ENSP00000478922.1; NM_001243925.2; NP_001230854.1.
DR   UCSC; uc003day.3; human.
DR   CTD; 7867; -.
DR   DisGeNET; 7867; -.
DR   GeneCards; MAPKAPK3; -.
DR   HGNC; HGNC:6888; MAPKAPK3.
DR   HPA; ENSG00000114738; Group enriched (bone marrow, heart muscle, skeletal muscle, tongue).
DR   MalaCards; MAPKAPK3; -.
DR   MIM; 602130; gene.
DR   MIM; 617111; phenotype.
DR   neXtProt; NX_Q16644; -.
DR   OpenTargets; ENSG00000114738; -.
DR   Orphanet; 466718; Martinique crinkled retinal pigment epitheliopathy.
DR   PharmGKB; PA30632; -.
DR   VEuPathDB; HostDB:ENSG00000114738; -.
DR   eggNOG; KOG0604; Eukaryota.
DR   GeneTree; ENSGT00940000154089; -.
DR   InParanoid; Q16644; -.
DR   OMA; DRAMWED; -.
DR   OrthoDB; 843707at2759; -.
DR   PhylomeDB; Q16644; -.
DR   TreeFam; TF312891; -.
DR   PathwayCommons; Q16644; -.
DR   Reactome; R-HSA-171007; p38MAPK events.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   SignaLink; Q16644; -.
DR   SIGNOR; Q16644; -.
DR   BioGRID-ORCS; 7867; 14 hits in 1112 CRISPR screens.
DR   ChiTaRS; MAPKAPK3; human.
DR   EvolutionaryTrace; Q16644; -.
DR   GeneWiki; MAPKAPK3; -.
DR   GenomeRNAi; 7867; -.
DR   Pharos; Q16644; Tchem.
DR   PRO; PR:Q16644; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q16644; protein.
DR   Bgee; ENSG00000114738; Expressed in apex of heart and 199 other tissues.
DR   ExpressionAtlas; Q16644; baseline and differential.
DR   Genevisible; Q16644; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0009931; F:calcium-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0005516; F:calmodulin binding; IBA:GO_Central.
DR   GO; GO:0004683; F:calmodulin-dependent protein kinase activity; IBA:GO_Central.
DR   GO; GO:0004708; F:MAP kinase kinase activity; TAS:ProtInc.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IBA:GO_Central.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0044351; P:macropinocytosis; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IBA:GO_Central.
DR   GO; GO:0034097; P:response to cytokine; IDA:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 4.10.1170.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR027442; MAPKAPK_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cytoplasm; Disease variant; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..382
FT                   /note="MAP kinase-activated protein kinase 3"
FT                   /id="PRO_0000086293"
FT   DOMAIN          44..304
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..34
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          307..343
FT                   /note="Autoinhibitory helix"
FT                   /evidence="ECO:0000250"
FT   REGION          345..369
FT                   /note="p38 MAPK-binding site"
FT                   /evidence="ECO:0000250"
FT   REGION          357..382
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           335..344
FT                   /note="Nuclear export signal (NES)"
FT                   /evidence="ECO:0000250"
FT   MOTIF           350..353
FT                   /note="Bipartite nuclear localization signal 1"
FT                   /evidence="ECO:0000250"
FT   MOTIF           364..368
FT                   /note="Bipartite nuclear localization signal 2"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        368..382
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        166
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         50..58
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         73
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         201
FT                   /note="Phosphothreonine; by MAPK14"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UMW7"
FT   MOD_RES         251
FT                   /note="Phosphoserine; by MAPK14"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         307
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         313
FT                   /note="Phosphothreonine; by MAPK14"
FT                   /evidence="ECO:0000250"
FT   VARIANT         28
FT                   /note="P -> S (in a glioblastoma multiforme sample; somatic
FT                   mutation; dbSNP:rs375412266)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040755"
FT   VARIANT         105
FT                   /note="E -> A (in an ovarian endometrioid sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040756"
FT   VARIANT         173
FT                   /note="L -> P (in MDPT3; decreased localization to the
FT                   nucleus; dbSNP:rs886037913)"
FT                   /evidence="ECO:0000269|PubMed:26744326"
FT                   /id="VAR_077085"
FT   VARIANT         276
FT                   /note="D -> Y (in dbSNP:rs56107897)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040757"
FT   MUTAGEN         73
FT                   /note="K->M: Higher affinity toward PCH2."
FT                   /evidence="ECO:0000269|PubMed:15563468"
FT   HELIX           39..41
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   STRAND          43..53
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   STRAND          56..63
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   TURN            64..66
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   STRAND          69..78
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           79..91
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   STRAND          100..108
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   STRAND          111..119
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           126..131
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           140..159
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           169..171
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   STRAND          172..175
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   STRAND          183..185
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           218..237
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   TURN            267..269
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   STRAND          271..273
FT                   /evidence="ECO:0007829|PDB:3R1N"
FT   HELIX           275..284
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           289..291
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           295..300
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           302..305
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           307..309
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           317..323
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           325..327
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   HELIX           328..343
FT                   /evidence="ECO:0007829|PDB:3FHR"
FT   STRAND          344..346
FT                   /evidence="ECO:0007829|PDB:7NRB"
SQ   SEQUENCE   382 AA;  42987 MW;  405F958B7F54E6F3 CRC64;
     MDGETAEEQG GPVPPPVAPG GPGLGGAPGG RREPKKYAVT DDYQLSKQVL GLGVNGKVLE
     CFHRRTGQKC ALKLLYDSPK ARQEVDHHWQ ASGGPHIVCI LDVYENMHHG KRCLLIIMEC
     MEGGELFSRI QERGDQAFTE REAAEIMRDI GTAIQFLHSH NIAHRDVKPE NLLYTSKEKD
     AVLKLTDFGF AKETTQNALQ TPCYTPYYVA PEVLGPEKYD KSCDMWSLGV IMYILLCGFP
     PFYSNTGQAI SPGMKRRIRL GQYGFPNPEW SEVSEDAKQL IRLLLKTDPT ERLTITQFMN
     HPWINQSMVV PQTPLHTARV LQEDKDHWDE VKEEMTSALA TMRVDYDQVK IKDLKTSNNR
     LLNKRRKKQA GSSSASQGCN NQ
//
